ActiveMSers Forums  

Go Back   ActiveMSers Forums > ActiveMSers.org Forums > Dave's SCT Journey

Reply
 
Thread Tools Display Modes
  #1  
Old 06-02-2019, 06:41 PM
ActiveMSers's Avatar
ActiveMSers ActiveMSers is online now
Dave @ ActiveMSers
 
Join Date: Jun 2008
Location: Albuquerque, NM
Posts: 3,719
Default Quality of Life after HSCT in MS and Systemic Sclerosis

Health Professionals in Rheumatology Abstracts
Poster Presentations
THURSDAY, 13 JUNE 2019
HPR Patients’ perspectives, functioning and health (descriptive: qualitative or quantitative)

THU0712-HPR QUALITY OF LIFE OF PATIENTS WITH MULTIPLE SCLEROSIS AND SYSTEMIC SCLEROSIS SUBMITTED TO HSCT: A COMPARATIVE AND LONGITUDINAL STUDY

Érika Arantes de Cardoso, et al

Abstract

Background
Multiple Sclerosis (MS) and Systemic Sclerosis (SSc) are chronic autoimmune diseases that comprise physical and psychological aspects. Disease progression is usually associated with a continuous decline in quality of life. In this devastating scenario, hematopoietic stem cell transplantation (HSCT) has emerged as an alternative treatment, improving physical outcomes and, at the same time, restoring a more normal life. Quality of life evaluations may be used to measure the effects of therapeutic interventions, considering their impact on patient life in the medium and long term.

Objectives
To evaluate the impact of HSCT on the Quality of Life (QoL) of SSc (G1) and MS (G2).

Methods
In this comparative, longitudinal, cross-sectional study, 56 patients (22 SSc and 34 MS) were included. The Medical Outcomes Study Short-Form 36 (MOS SF-36) scale, used for data collection, mainly assesses the physical health component (PHC) and the mental health component (MHC). The PHC encompasses the following domains: physical functioning (PF), role limitations due to physical problems (RPF), bodily pain (P) and general health perceptions (GHP). The MHC comprises: vitality (VIT), social functioning (SRF), role limitations due to emotional role functioning (ERF) and general mental health (MH). The results of each domain range from 0 to 100, where zero represents the worst and 100 the best state of health. Data were collected at admission and at 2-years after transplantation. Results underwent statistical analysis. Significance levels were established at p<0.05.

Results
The study included intragroup comparisons (Pre vs post-HSCT; Table 1) and intergroup comparisons (G1 vs G2; Table 2). In the intragroup analyses, comparing pre and post-HSCT scores, there was general improvement in both disease groups, especially in G2. The intergroup comparisons indicate that before HSCT patients in G1 had better FP than those in G2 (p = 0.03). The other aspects were not significantly different between groups. After HSCT, patients in G2 had a better QoL scores in P (p = 0.4338), GHP (p = 0.0001) and MH (p = 0.0049).

Conclusion These results may be interpreted as positive outcomes of HSCT for MS and SSc. However, our data indicate that HSCT may benefit patients with MS (G2) more than those with SSc (G1).

http://dx.doi.org/10.1136/annrheumdis-2019-eular.150

TABLES: https://ard.bmj.com/content/78/Suppl_2/652.3
__________________
Dave Bexfield
ActiveMSers
Reply With Quote
Reply

Thread Tools
Display Modes

Posting Rules
You may not post new threads
You may not post replies
You may not post attachments
You may not edit your posts

BB code is On
Smilies are On
[IMG] code is On
HTML code is Off
Forum Jump


All times are GMT -4. The time now is 07:34 AM.


Powered by vBulletin® Version 3.7.0
Copyright ©2000 - 2019, Jelsoft Enterprises Ltd.
ActiveMSers